NASDAQ:ATRC - AtriCure Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $28.54 -0.44 (-1.52 %) (As of 07/16/2018 12:18 PM ET)Previous Close$28.66Today's Range$28.18 - $28.7752-Week Range$14.88 - $30.96Volume1,531 shsAverage Volume249,153 shsMarket Capitalization$1.02 billionP/E Ratio-34.11Dividend YieldN/ABeta0.25 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio. Receive ATRC News and Ratings via Email Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical SymbolNASDAQ:ATRC CUSIP04963C20 Webwww.atricure.com Phone513-755-4100 Debt Debt-to-Equity Ratio0.34 Current Ratio3.15 Quick Ratio2.31 Price-To-Earnings Trailing P/E Ratio-34.11 Forward P/E Ratio-33.19 P/E GrowthN/A Sales & Book Value Annual Sales$174.72 million Price / Sales5.72 Cash FlowN/A Price / CashN/A Book Value$4.67 per share Price / Book6.11 Profitability EPS (Most Recent Fiscal Year)($0.83) Net Income$-26,890,000.00 Net Margins-14.88% Return on Equity-16.92% Return on Assets-9.99% Miscellaneous Employees570 Outstanding Shares35,040,000Market Cap$1,015.46 AtriCure (NASDAQ:ATRC) Frequently Asked Questions What is AtriCure's stock symbol? AtriCure trades on the NASDAQ under the ticker symbol "ATRC." How were AtriCure's earnings last quarter? AtriCure Inc. (NASDAQ:ATRC) posted its quarterly earnings results on Thursday, April, 26th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by $0.04. The medical device company earned $46.99 million during the quarter, compared to analysts' expectations of $45.43 million. AtriCure had a negative return on equity of 16.92% and a negative net margin of 14.88%. AtriCure's revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period last year, the company earned ($0.32) earnings per share. View AtriCure's Earnings History. When is AtriCure's next earnings date? AtriCure is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for AtriCure. What price target have analysts set for ATRC? 5 equities research analysts have issued 1 year price objectives for AtriCure's stock. Their forecasts range from $30.00 to $35.00. On average, they anticipate AtriCure's stock price to reach $32.25 in the next twelve months. This suggests a possible upside of 13.8% from the stock's current price. View Analyst Ratings for AtriCure. What is the consensus analysts' recommendation for AtriCure? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about AtriCure stock? Here are some recent quotes from research analysts about AtriCure stock: 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (6/26/2018) 2. Needham & Company LLC analysts commented, "We have increased confidence in ATRC’s ability to sustain strong revenue growth and to drive upside to consensus estimates given: 1) strong Open-Heart Ablation growth driven by society guidelines and increasing penetration, 2) strong AtriClip growth driven by new products with higher prices, 3) conservative guidance, and 4) easing comps, particularly in 2H18. Additionally, we expect ATRC’s analyst meeting (6/26 in NYC) to serve as a nearer-term catalyst and results from its CONVERGE trial to serve a a significant longer-term catalyst in 2H19. Given this, we raise our price target to $32 from $26 and reiterate our Buy rating." (6/18/2018) Who are some of AtriCure's key competitors? Some companies that are related to AtriCure include Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY) and OraSure Technologies (OSUR). Who are AtriCure's key executives? AtriCure's management team includes the folowing people: Mr. Michael H. Carrel, CEO, Pres & Director (Age 47)Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 43)Mr. Douglas J. Seith, Chief Operating Officer (Age 52)Mr. Salvatore Privitera, Chief Technology Officer (Age 51)Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 40) Has AtriCure been receiving favorable news coverage? Press coverage about ATRC stock has trended somewhat positive on Monday, according to Accern Sentiment. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AtriCure earned a media sentiment score of 0.09 on Accern's scale. They also assigned news stories about the medical device company an impact score of 48.13 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Who are AtriCure's major shareholders? AtriCure's stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (2.56%), Bank of Montreal Can (0.11%) and Campbell & CO Investment Adviser LLC (0.03%). Company insiders that own AtriCure stock include Andrew L Lux, B Kristine Johnson, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar and Regina E Groves. View Institutional Ownership Trends for AtriCure. Which major investors are selling AtriCure stock? ATRC stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold AtriCure company stock in the last year include Elizabeth D Krell, Justin J Noznesky, M Andrew Wade and Mark A Collar. View Insider Buying and Selling for AtriCure. Which major investors are buying AtriCure stock? ATRC stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Campbell & CO Investment Adviser LLC. Company insiders that have bought AtriCure stock in the last two years include B Kristine Johnson and Regina E Groves. View Insider Buying and Selling for AtriCure. How do I buy shares of AtriCure? Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AtriCure's stock price today? One share of ATRC stock can currently be purchased for approximately $28.34. How big of a company is AtriCure? AtriCure has a market capitalization of $1.02 billion and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe. How can I contact AtriCure? AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100. MarketBeat Community Rating for AtriCure (NASDAQ ATRC)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 325 (Vote Outperform)Underperform Votes: 197 (Vote Underperform)Total Votes: 522MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: What do investors mean by earnings per share?